

Press release 2011-04-19



Overwhelming response to the expanded C-RAD product range presented at the ESTRO meeting in London, UK

C-RAD AB with its three fully owned subsidiaries are all active in the field of radiation therapy. The company attended the European oncology and physicist meeting ESTRO in London, UK, 8-12 May 2011. The Catalyst™ system was presented for the first time, along with the already established Sentinel™ and GEMini™ products.

The annual ESTRO meeting is the largest recurring event in Europe where companies in the radiation therapy market meet with end customers and partners. At this year's event, the C-RAD booth was centrally located close to all the major LINAC vendors.

The new Catalyst™ system, with its unique features for real-time verification and visual guidance, drew a lot of attention and was constantly demonstrated during the show's opening hours to end customers as well as vendors. There was also a continued high interest for the Sentinel™ and GEMini™ systems. Many new leads were identified, and discussions with industrial partners were held for all the products in the C-RAD product range.

Parallel to the technical exhibition, the university clinics were publishing their newest findings. The university hospital in Lund detailed their clinical use of the Sentinel™ system, which has proven to result in an increase in patient throughput by 50% with a significant reduction in non-prescribed dose to healthy tissue. The university hospital in Uppsala presented their results on the clinical accuracy of the Sentinel™ system.

The Paracelsus Medical University in Salzburg reported their initial findings on comparing the GEMini™ ED detector to a conventional amorphous silicon detector, confirming the superior speed of the GEMini™ detector.

Erik Hedlund, CEO, C-RAD AB:

"The overwhelming response received at this year's ESTRO meeting again confirms the demand for the C-RAD product range in the radiation therapy market. The official launch of the Catalyst™ system generated tremendous interest. Negotiations for further orders are being finalized."

For further information:

Erik Hedlund, CEO C-RAD AB, Telefon 018 - 66 69 31, E-post erik.hedlund@c-rad.se

About C-RAD AB

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 19 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.